Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Equity (2019 - 2025)

BioNexus Gene Lab's Return on Equity history spans 7 years, with the latest figure at 0.39% for Q4 2025.

  • Quarterly results put Return on Equity at 0.39% for Q4 2025, down 21.0% from a year ago — trailing twelve months through Dec 2025 was 0.39% (down 21.0% YoY), and the annual figure for FY2025 was 0.35%, down 18.0%.
  • Return on Equity for Q4 2025 was 0.39% at BioNexus Gene Lab, down from 0.32% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.11% in Q4 2021 to a low of 0.41% in Q3 2023.
  • The 5-year median for Return on Equity is 0.09% (2023), against an average of 0.13%.
  • The sharpest move saw Return on Equity plummeted -40bps in 2023, then skyrocketed 32bps in 2024.
  • Year by year, Return on Equity stood at 0.11% in 2021, then plummeted by -149bps to 0.05% in 2022, then plummeted by -407bps to 0.27% in 2023, then soared by 36bps to 0.18% in 2024, then plummeted by -121bps to 0.39% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.39%, 0.32%, and 0.38% for Q4 2025, Q3 2025, and Q2 2025 respectively.